GRAIL Company

GRAIL is poised to detect cancer early by combining high-intensity sequencing of unprecedented breadth and depth with the techniques of modern data science. Through what we believe to be one of the largest clinical study programs ever pursued in genomic medicine, GRAIL is creating vast datasets to develop evidence supporting our products. Grail develops a pan-cancer screening test designed to detect cancer early. Its pan-cancer screening test measures circulating nucleic acids in blood using high-intensity sequencing, population-scale clinical trials, enabling doctors to develop blood tests for early-stage cancer detection.
Technology: Personalized Diagnostics
Industry: Precision Medicine
Headquarters: Menlo Park
Founded Date: 2016
Employees Number: 201-500
Funding Status: Late Stage Venture

Visit Website
Register and Claim Ownership